GlassScriptPhysician profile
James O Smith
NPI 1437209889
$4,628.22
in general payments reported to CMS, 2019-2025
31 companies · $37.39 in 2025
The $37.39 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,560 · 2020: $495 · 2021: $851 · 2022: $471 · 2023: $515 · 2024: $699 · 2025: $37.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $629.07 | 2019-2024 | Farxiga |
| Pfizer INC. | $575.98 | 2019-2023 | |
| Glaxosmithkline, LLC. | $412.68 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $354.41 | 2019-2021 | |
| Amgen INC. | $307.82 | 2020-2024 | Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.74 | 2020-2024 | Xifaxan, Trulance |
| Allergan, INC. | $253.95 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $229.47 | 2019-2021 | |
| Lilly USA, LLC | $216.08 | 2020-2024 | Mounjaro |
| Novo Nordisk INC | $170.70 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $149.49 | 2021-2024 | Vraylar |
| Genentech USA, INC. | $129.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.05 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $115.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $114.29 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $89.81 | 2022-2024 | Freestyle Libre 3, Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.46 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.94 | 2022 | |
| Idorsia Pharmaceuticals US INC | $62.72 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $50.39 | 2021-2022 | |
| Edwards Lifesciences Corporation | $37.39 | 2025 | Sapien 3 Ultra Resilia |
| Dexcom, INC. | $34.95 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $28.57 | 2023 | Rexulti |
| Biogen, INC. | $21.05 | 2020 | |
| Amarin Pharma, INC. | $20.91 | 2019 | |
| Medline Industries LP | $20.56 | 2024 | |
| Eisai INC. | $14.76 | 2021 | |
| Exact Sciences Corporation | $14.18 | 2023 | Cologuard Collection Kit |
| Agios Pharmaceuticals, INC. | $14.15 | 2023 | Pyrukynd |
| Kowa Pharmaceuticals America, INC. | $13.80 | 2023 | Livalo, Seglentis |
| Snap Diagnostics LLC | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.